Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change ...

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed ...

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

It’s easy to assume that more data = better models = faster identification. With AI, you can extract associations between ...

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing. There have been over 40 rounds of layoffs announced this year as of April 30, compared to more ...

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new ...

PathAI makes AI models that help with the analysis of patient tissue samples and diagnostic tools. Roche has partnered with ...

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...

Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a ...

Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.

Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA ...

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the ...